News about Global Pharma

GSK Gains Exclusive Rights to Syndivia's Prostate Cancer ADC

GSK has obtained exclusive rights from Syndivia for a preclinical Antibody-Drug Conjugate (ADC) targeting metastatic Castration-Resistant Prostate Cancer (mCRPC), addressing an urgent need for novel therapies. The agreement expands GSK’s oncology pipeline with a potential best-in-class ADC designed to deliver enhanced anti-tumour activity.

Global Pharma | 27/10/2025 | By Dineshwori |  427

Merck KGaA Reports Sustained Efficacy and Safety of OGSIVEO in Phase-III Desmoid Tumour Study

Merck KGaA has released long-term phase-III data showing that OGSIVEO treatment for up to four years continues to deliver durable tumour reductions, improved response rates, sustained symptom relief, and a consistent safety profile in patients with desmoid tumours.

Global Pharma | 27/10/2025 | By Dineshwori |  413

Eli Lilly And Cipla Partner to Distribute Yurpeak (Tirzepatide) in India

Eli Lilly and Cipla have signed an agreement to distribute and promote tirzepatide in India under a second brand name, Yurpeak.

Global Pharma | 27/10/2025 | By Dineshwori |  697

Chugai Pharmaceutical to Acquire Renalys Pharma to Accelerate Access to Sparsentan Across Asia

Chugai Pharmaceutical has entered into a definitive stock purchase agreement to acquire Renalys Pharma, a company focused on advancing innovative therapies for chronic kidney disease across Asia.

Global Pharma | 24/10/2025 | By Dineshwori |  670

SystImmune and BMS Present Phase I Results of EGFR x HER3 Bispecific ADC at ESMO 2025

Iza-bren, a potentially first-in-class EGFR x HER3 bispecific Antibody-Drug Conjugate (ADC), is jointly developed by SystImmune and Bristol Myers Squibb under a collaboration and exclusive licence agreement in territories outside of Mainland China.

Global Pharma | 21/10/2025 | By Dineshwori |  508

FDA Approves Oral Semaglutide by Novo Nordisk for CV Risk Reduction in Adults with Type 2 Diabetes

Rybelsus (Semaglutide) tablets, available in 7 mg and 14 mg doses, is the only FDA-approved oral GLP-1 therapy, and is now indicated to lower the risk of Major Adverse Cardiovascular Events (MACE)—including CV death, heart attack, or stroke—in adults with type 2 diabetes at high cardiovascular risk.

Global Pharma | 21/10/2025 | By Dineshwori |  396

Aspire Pharma acquires Charlwood Pharma

Aspire Pharma, a UK-based specialty generics pharma business, has announced the acquisition of Charlwood Pharma Ltd — a privately-owned company specialising in the research and development of niche generic medicines. The deal marks the culmination of a successful multi-year collaboration between the two organisations.

Global Pharma | 21/10/2025 | By Dineshwori |  484

Waters Corporation Unveils Xevo Charge Detection MS for Advanced Biomolecule Analysis

The new Xevo CDMS system by Waters Corporation enables measurement of large biomolecules to support Research and Development (R&D) in gene and protein-based therapies.

Global Pharma | 21/10/2025 | By Dineshwori |  386

ManaMed Secures FDA Clearance for Next-Generation Tubeless Compression System, PlasmaFlow X

ManaMed, a US-based global leader in orthopedic mobility and post-operative rehabilitation equipment, has received FDA 510(k) clearance for PlasmaFlow X, its next-generation tubeless sequential compression system designed to redefine recovery and enhance patient comfort.

Global Pharma | 21/10/2025 | By Dineshwori |  398

SK Biopharmaceuticals, Eurofarma Launch Joint Venture in Canada to Advance AI-Based Epilepsy Management

Korean biotech company SK Biopharmaceuticals and Brazil-based Eurofarma have established a joint venture, Mentis Care, in Canada to commercialise an AI-powered epilepsy management platform. The new company marks SK Biopharmaceuticals’ full-scale expansion into digital healthcare beyond its innovative drug development portfolio.

Global Pharma | 21/10/2025 | By Dineshwori |  567